ES2160495B1 - Treatment of endotoxic shock by inhibiting production of pro-inflammatory cytokines - Google Patents

Treatment of endotoxic shock by inhibiting production of pro-inflammatory cytokines

Info

Publication number
ES2160495B1
ES2160495B1 ES9901235A ES9901235A ES2160495B1 ES 2160495 B1 ES2160495 B1 ES 2160495B1 ES 9901235 A ES9901235 A ES 9901235A ES 9901235 A ES9901235 A ES 9901235A ES 2160495 B1 ES2160495 B1 ES 2160495B1
Authority
ES
Spain
Prior art keywords
production
pro
treatment
inflammatory cytokines
endotoxic shock
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES9901235A
Other languages
Spanish (es)
Other versions
ES2160495A1 (en
Inventor
Gomariz Rosa Perez
Martinez Javier Leceta
Mora Mario Delgado
Mora Carmen Martinez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Complutense de Madrid
Original Assignee
Universidad Complutense de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES009800814A external-priority patent/ES2138561B1/en
Application filed by Universidad Complutense de Madrid filed Critical Universidad Complutense de Madrid
Priority to ES9901235A priority Critical patent/ES2160495B1/en
Priority to PCT/ES2000/000197 priority patent/WO2000074708A1/en
Priority to CA002345030A priority patent/CA2345030A1/en
Priority to DE60002143T priority patent/DE60002143T2/en
Priority to EP00931296A priority patent/EP1103270B1/en
Priority to AU49277/00A priority patent/AU4927700A/en
Priority to PT00931296T priority patent/PT1103270E/en
Priority to AT00931296T priority patent/ATE237347T1/en
Publication of ES2160495A1 publication Critical patent/ES2160495A1/en
Publication of ES2160495B1 publication Critical patent/ES2160495B1/en
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Treatment of endotoxic shock in a mammal comprises administering, in a vehicle, an agent (I) that inhibits production of tumor necrosis factor (TNF) or interleukin-6 (IL-6). ACTIVITY : Antiinflammatory; antibacterial; immunosuppressive. MECHANISM OF ACTION : Inhibiting production of pro-inflammatory cytokines. Murine peritoneal macrophages were stimulated with lipopolysaccharide (LPS; 10 ng/ml) in presence of 0.001 mu M vasoactive intestinal peptide (VIP). The production of IL-6 was about 800 ng/ml in absence of VIP but only about 160 ng/ml in its presence. Production of TNF by the same cells was also suppressed, e.g. the maximum level was reduced from about 1400 pg/ml to about 600 pg/ml.
ES9901235A 1998-04-17 1999-06-04 Treatment of endotoxic shock by inhibiting production of pro-inflammatory cytokines Expired - Fee Related ES2160495B1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
ES9901235A ES2160495B1 (en) 1998-04-17 1999-06-04 Treatment of endotoxic shock by inhibiting production of pro-inflammatory cytokines
EP00931296A EP1103270B1 (en) 1999-06-04 2000-06-02 Treatment of autoimmune diseases in mammals
CA002345030A CA2345030A1 (en) 1999-06-04 2000-06-02 Composition and method for the treatment of endotoxic shock and inflammatory and autoimmune diseases in mammals
DE60002143T DE60002143T2 (en) 1999-06-04 2000-06-02 TREATMENT OF AUTOIMMUNE DISEASES IN MAMMALS
PCT/ES2000/000197 WO2000074708A1 (en) 1999-06-04 2000-06-02 Method for treating endotoxic shock and inflammatory and autoimmune diseases in mammals
AU49277/00A AU4927700A (en) 1999-06-04 2000-06-02 Method for treating endotoxic shock and inflammatory and autoimmune diseases in mammals
PT00931296T PT1103270E (en) 1999-06-04 2000-06-02 TREATMENT OF AUTO-IMMUNE DISEASES IN MAMMALS
AT00931296T ATE237347T1 (en) 1999-06-04 2000-06-02 TREATMENT OF AUTOIMMUNE DISEASES IN MAMMALS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009800814A ES2138561B1 (en) 1998-04-17 1998-04-17 USE OF VIP PEPTIDES AND PACAP IN THE TREATMENT OF ENDOTOXIC SHOCK IN MAMMALS.
ES9901235A ES2160495B1 (en) 1998-04-17 1999-06-04 Treatment of endotoxic shock by inhibiting production of pro-inflammatory cytokines

Publications (2)

Publication Number Publication Date
ES2160495A1 ES2160495A1 (en) 2001-11-01
ES2160495B1 true ES2160495B1 (en) 2002-09-16

Family

ID=26155143

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9901235A Expired - Fee Related ES2160495B1 (en) 1998-04-17 1999-06-04 Treatment of endotoxic shock by inhibiting production of pro-inflammatory cytokines

Country Status (1)

Country Link
ES (1) ES2160495B1 (en)

Also Published As

Publication number Publication date
ES2160495A1 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
WO2001098331A3 (en) Glucagon-like peptide-1 analogs
GB2249268B (en) Double tank pinch trigger pump water gun
IL138665A0 (en) Peptide factor
CA2329922A1 (en) Imidazo pyridine derivatives which inhibit gastric acid secretion
NO954281L (en) Water Purification System
EP1992641A3 (en) GLP-1 analogues
CA2123593A1 (en) Method of Treating TNF-Dependent Inflammation Using Tumor Necrosis Factor Antagonists
WO1998009618A3 (en) Graft survival prolongation with porphyrins
HK1033548A1 (en) Cd154 blockade therapy for pancreatic islet tissuetransplantation in primates
ES2160495B1 (en) Treatment of endotoxic shock by inhibiting production of pro-inflammatory cytokines
EP0604647A4 (en) Alleviation of symptoms associated with inflammatory disease states.
NO20053364L (en) CC chemokine mutants for liver disease.
EP0971725A4 (en) Methods for treatment of scar tissue
AU1351302A (en) Inhibition or reversal of skin aging by actin-sequestering peptides
HUP0101514A2 (en) Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
CA2114862A1 (en) Process for the synthesis of semi-synthetic glycosaminoglycans with heparin or heparan structure modified in position 2 of the .alpha.-l-iduronic-2-0-sulfate acid
EP1287832A3 (en) Use of leukemia inhibitory factor antagonist
EP0653209A4 (en) Remedy for inflammatory intestinal diseases.
IT1284143B1 (en) SEMI-SYNTHETIC HEPARANSULPHATES WITH HIGH ANTIMETASTIC ACTIVITY AND REDUCED HEMORRAGIC RISK
IT8722871A0 (en) MODULAR LOW VOLTAGE ELECTRICAL PANEL, FOR MODULAR EQUIPMENT.
HAYASHI Role of human engineering on the robotization
Podgorski Classical Hinduism Documenta Missionalia
EP0937718A4 (en) Antibiotic tkr2648 and process for producing the same
李胜利 et al. Study on structural stability of RE/Fe multilayers
UA88862C2 (en) Glucagon-like peptide-1 analogs

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20011101

Kind code of ref document: A1

Effective date: 20011101

FD2A Announcement of lapse in spain

Effective date: 20190926